ANBT
EWTX icon

American National Bank & Trust’s Edgewise Therapeutics EWTX Stock Holding History

American National Bank & Trust’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$32 – 721
2025
Q3 		$32 Hold
2
– – ﹤0.01% 636
2025
Q2 		$26 Buy
+2
New +$29 ﹤0.01% 650

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

American National Bank & Trust's EWTX Position: Q4 2025 in Review

American National Bank & Trust sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 2 shares — an estimated $32 sold.

American National Bank & Trust first reported a position in EWTX in Q2 2025 and held it in 2 quarters. The position peaked at $32 in Q3 2025. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • American National Bank & Trust reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
  • American National Bank & Trust sold 2 Edgewise Therapeutics shares in Q4 2025, an estimated $32.
  • American National Bank & Trust first reported a position in Edgewise Therapeutics in Q2 2025 and held it in 2 quarters.
  • American National Bank & Trust's Edgewise Therapeutics position peaked at $32 in Q3 2025.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on American National Bank & Trust's 13F filing for Q4 2025, filed 20 Jan 2026.